BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 11/07/2025 pm IST			5-day change	1st Jan Change
184.30 ^SEK	-2.85%		-0.86%	-7.62%

17/06	Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	FW
13/06	BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	MT

Goldman Sachs lowers target price for Bioarctic to SEK 237 (267), reiterates buy recommendation - BN

Published on 02/06/2025 at 09:48

Go to the original article.
Legal disclaimer

Latest news about BioArctic AB

Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	17/06	FW
BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	13/06	MT
BioArctic to Initiate Next Cohorts in Exidavnemab Phase 2a Study After Positive Safety Review	13/06	CI
Bioarctic initiates next step in Exist study following positive safety evaluation	13/06	FW
Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review	13/06	RE
BioArctic AB - Analyst/Investor Day	03/06
Bioarctic will present its ambitions for 2030 during its Capital Markets Day.	02/06	FW
Goldman Sachs lowers target price for Bioarctic to SEK 237 (267), reiterates buy recommendation - BN	02/06	FW
BioArctic AB, Q1 2025 Earnings Call, May 21, 2025	23/05
EU Committee Backs BioArctic's Exidavnemab for Multiple System Atrophy in EU	22/05	MT
Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU	22/05	RE
Bioarctic receives positive opinion in the EU for orphan drug designation for exidavnemab	22/05	FW
EMA Committee recommends orphan drug designation for Bioarctics' exidavnemab for multiple system atrophy (R)	22/05	FW
EMA recommends safety classification of Bioarctics' exidavnemab for multiple system atrophy	22/05	FW
Bioarctic AB Announces That the European Medicines Agency Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation to Exidavnemab for the Treatment of Multiple System Atrophy	22/05	CI
Stockholm Bullets - Cinclus Pharma surges on commercialization agreement	22/05	FW
Eli Lilly's Alzheimer's treatment approved in Australia	22/05	FW
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	21/05	CI
Bioarctic increases sales and operating profit (update)	21/05	FW
Bioarctic increases sales and operating profit	21/05	FW
Recovery on the Stockholm Stock Exchange, OMXS30 index rose 0.2 percent.	19/05	FW
Bioarctic celebrates FDA announcement on blood test, more people will be able to receive treatment - Di	19/05	FW
Stockholm Bullets - Bioarctic rises on FDA announcement regarding blood test	19/05	FW
FDA approves first blood test for detecting Alzheimer's	19/05	FW
Stockholm Bullets - Nibe declines on report	15/05	FW

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

116

Sector

Biotechnology & Medical Research

Calendar

28/08 - Q2 2025 Earnings Release

More about the company